Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-07-17 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于回购公司股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from a company about its plan to repurchase its own shares. It includes specifics about the repurchase amount, price limits, purpose (such as conversion of convertible bonds and employee stock plans), funding source, implementation period, and risk factors. It also contains board meeting resolutions and independent director opinions related to the share repurchase. The content is focused on the company's share buyback program rather than financial results, management changes, or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back or selling its own shares. The document length is over 7,000 characters and contains substantive details about the repurchase plan, not just a brief announcement or reference to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is POS with high confidence.
2023-07-17 Chinese
第五届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the fifth supervisory board's fourth meeting of the company. It includes specific decisions about a share repurchase plan, including purpose, conditions, methods, price range, quantity, funding sources, implementation period, and authorization to management. It also discusses the use of idle raised funds and self-owned funds for cash management. The document is a formal meeting resolution announcement rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on corporate governance decisions and approvals. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for announcements that do not fit other specific categories and are regulatory in nature.
2023-07-17 Chinese
2023年半年度业绩预告
Regulatory Filings Classification · 95% confidence The document is a 2023 half-year performance forecast (业绩预告) for the period January 1 to June 30, 2023, issued by the company. It contains estimated financial results, including net profit and explanations for performance changes. It explicitly states that the data is preliminary and unaudited, and the final detailed financial data will be disclosed in the 2023 half-year report. The document length is about 1000 characters, which is relatively short and mainly serves as a performance forecast announcement rather than a full interim report with actual financial statements. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) announcing the earnings forecast and related information.
2023-07-13 Chinese
关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1009 characters) from a company about its wholly owned subsidiary obtaining a medical device registration certificate. It includes details about the product, registration number, validity, and impact on the company. There is no financial data, no mention of a report being attached or published, and no regulatory certification or officer attestation. The content is an official company announcement about a regulatory approval related to product registration, which does not fit into financial reports, earnings, management changes, or other specific categories. It is best classified as a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other categories.
2023-07-03 Chinese
关于2023年第二季度健帆转债转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares for the second quarter of 2023 by 健帆生物科技集团股份有限公司. It details the bond issuance, conversion prices adjustments, the number of bonds converted, and the resulting changes in share capital structure. The document is relatively short (3657 characters) and focuses on the bond conversion and share capital changes rather than providing comprehensive financial statements or analysis. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a general regulatory filing or a report publication announcement. The content fits best with a Capital/Financing Update (CAP) as it updates on the company's convertible bond conversions and related capital structure changes.
2023-07-03 Chinese
奋斗者二号员工持股计划第一次持有人会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the first meeting of holders of an employee stock ownership plan (奋斗者二号员工持股计划). It details the meeting attendance, voting results, and decisions such as the establishment of a management committee and authorization of its powers. There is no financial data, earnings information, or regulatory certification. The document is a formal announcement of meeting resolutions related to employee shareholding plan governance, not a full report or financial statement. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement about internal governance and shareholder meeting outcomes related to an employee stock plan.
2023-06-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.